Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky

Professor Matt Galsky joins Alicia Morgans to share details of an analysis looking at FGFR mutations in patients who have received checkpoint inhibitor therapy on clinical trials.  In this study, Matt Galsky and colleagues examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. Using data derived from two clinical trials exploring CPI in metastatic urothelial carcinoma (UC), this analysis demonstrated no statistically significant difference in response rates in patients with FGFR3-mutant versus wild-type UC. In a result of this data, Matt Galsky and colleagues present hypothesis-generating data, suggesting that similar response rates may be explained by a "balancing out" of previously identified independent positive and negative predictors of CPI sensitivity compared with FGFR3 wild-type UC, FGFR3-mutant UC is associated with a similar tumor mutational burden, lower T-cell infiltration, but also lower stromal/transforming growth factor beta (TGF-β) signals.

Biography:

Matthew Galsky, MD Director of Genitourinary Medical Oncology, Tisch Cancer Institute, Professor of Medicine, Mount Sinai

Alicia Morgans, MD, MPH is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

 
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe